JP2012507499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507499A5 JP2012507499A5 JP2011533849A JP2011533849A JP2012507499A5 JP 2012507499 A5 JP2012507499 A5 JP 2012507499A5 JP 2011533849 A JP2011533849 A JP 2011533849A JP 2011533849 A JP2011533849 A JP 2011533849A JP 2012507499 A5 JP2012507499 A5 JP 2012507499A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- amino acid
- acid sequence
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 55
- 239000000203 mixture Substances 0.000 claims 47
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 44
- 102000006495 integrins Human genes 0.000 claims 26
- 108010044426 integrins Proteins 0.000 claims 26
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 18
- 108010048623 Collagen Receptors Proteins 0.000 claims 15
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 15
- 102000000507 Integrin alpha2 Human genes 0.000 claims 14
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 12
- 206010017758 gastric cancer Diseases 0.000 claims 12
- 201000011549 stomach cancer Diseases 0.000 claims 12
- 206010009944 Colon cancer Diseases 0.000 claims 10
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 10
- 206010038389 Renal cancer Diseases 0.000 claims 10
- 201000010982 kidney cancer Diseases 0.000 claims 10
- 201000007270 liver cancer Diseases 0.000 claims 10
- 208000014018 liver neoplasm Diseases 0.000 claims 10
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims 10
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 6
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims 5
- 206010005003 Bladder cancer Diseases 0.000 claims 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 5
- 206010014733 Endometrial cancer Diseases 0.000 claims 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 5
- 201000008808 Fibrosarcoma Diseases 0.000 claims 5
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 5
- 206010073069 Hepatic cancer Diseases 0.000 claims 5
- 108010017642 Integrin alpha2beta1 Proteins 0.000 claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 5
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 5
- 206010027145 Melanocytic naevus Diseases 0.000 claims 5
- 206010027406 Mesothelioma Diseases 0.000 claims 5
- 208000034578 Multiple myelomas Diseases 0.000 claims 5
- 208000007256 Nevus Diseases 0.000 claims 5
- 206010030113 Oedema Diseases 0.000 claims 5
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 5
- 206010061934 Salivary gland cancer Diseases 0.000 claims 5
- 206010041067 Small cell lung cancer Diseases 0.000 claims 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 5
- 206010047741 Vulval cancer Diseases 0.000 claims 5
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 5
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 5
- 230000002159 abnormal effect Effects 0.000 claims 5
- 210000004204 blood vessel Anatomy 0.000 claims 5
- 201000010881 cervical cancer Diseases 0.000 claims 5
- 208000029742 colonic neoplasm Diseases 0.000 claims 5
- 201000003914 endometrial carcinoma Diseases 0.000 claims 5
- 230000003325 follicular Effects 0.000 claims 5
- 201000003444 follicular lymphoma Diseases 0.000 claims 5
- 208000005017 glioblastoma Diseases 0.000 claims 5
- 201000009277 hairy cell leukemia Diseases 0.000 claims 5
- 201000010536 head and neck cancer Diseases 0.000 claims 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 5
- 201000002250 liver carcinoma Diseases 0.000 claims 5
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 5
- 201000005202 lung cancer Diseases 0.000 claims 5
- 208000020816 lung neoplasm Diseases 0.000 claims 5
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 5
- 230000000527 lymphocytic effect Effects 0.000 claims 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 5
- 201000001441 melanoma Diseases 0.000 claims 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 5
- 201000002528 pancreatic cancer Diseases 0.000 claims 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 5
- 201000002628 peritoneum cancer Diseases 0.000 claims 5
- 201000003804 salivary gland carcinoma Diseases 0.000 claims 5
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 201000002510 thyroid cancer Diseases 0.000 claims 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims 5
- 206010046766 uterine cancer Diseases 0.000 claims 5
- 208000012991 uterine carcinoma Diseases 0.000 claims 5
- 201000005102 vulva cancer Diseases 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 230000003902 lesion Effects 0.000 claims 4
- 208000025113 myeloid leukemia Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 230000002357 endometrial effect Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- -1 (c) position 78 is Chemical compound 0.000 claims 1
- 102000000905 Cadherin Human genes 0.000 claims 1
- 108050007957 Cadherin Proteins 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 102000004405 Collectins Human genes 0.000 claims 1
- 108090000909 Collectins Proteins 0.000 claims 1
- 102000014447 Complement C1q Human genes 0.000 claims 1
- 108010078043 Complement C1q Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004237 Decorin Human genes 0.000 claims 1
- 108090000738 Decorin Proteins 0.000 claims 1
- 241000204855 Echovirus E1 Species 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003560 cancer drug Substances 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000010118 platelet activation Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 239000004066 vascular targeting agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11193208P | 2008-11-06 | 2008-11-06 | |
| US61/111,932 | 2008-11-06 | ||
| PCT/IB2009/007351 WO2010052556A1 (en) | 2008-11-06 | 2009-11-05 | Treatment with anti-alpha2 integrin antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015062978A Division JP2015145397A (ja) | 2008-11-06 | 2015-03-25 | 抗α２インテグリン抗体を使用する処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507499A JP2012507499A (ja) | 2012-03-29 |
| JP2012507499A5 true JP2012507499A5 (OSRAM) | 2012-12-27 |
| JP5775458B2 JP5775458B2 (ja) | 2015-09-09 |
Family
ID=41528529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533849A Expired - Fee Related JP5775458B2 (ja) | 2008-11-06 | 2009-11-05 | 抗α２インテグリン抗体を使用する処置 |
| JP2015062978A Pending JP2015145397A (ja) | 2008-11-06 | 2015-03-25 | 抗α２インテグリン抗体を使用する処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015062978A Pending JP2015145397A (ja) | 2008-11-06 | 2015-03-25 | 抗α２インテグリン抗体を使用する処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8298531B2 (OSRAM) |
| EP (1) | EP2346903A1 (OSRAM) |
| JP (2) | JP5775458B2 (OSRAM) |
| AU (1) | AU2009312532B2 (OSRAM) |
| CA (1) | CA2742899A1 (OSRAM) |
| CL (1) | CL2011000931A1 (OSRAM) |
| DK (1) | DK201170284A (OSRAM) |
| EA (1) | EA201190002A1 (OSRAM) |
| MX (1) | MX2011004696A (OSRAM) |
| NZ (1) | NZ592436A (OSRAM) |
| WO (1) | WO2010052556A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201190002A1 (ru) * | 2008-11-06 | 2012-04-30 | Гленмарк Фармасьютикалс С.А. | Лечение антителами к интегрину альфа-2 |
| UY33578A (es) * | 2010-08-31 | 2012-03-30 | Sanofi Sa | PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS |
| CA3027071A1 (en) | 2011-01-14 | 2013-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| CA2840175C (en) | 2011-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
| JP7462566B2 (ja) * | 2018-03-16 | 2024-04-05 | ブリストル－マイヤーズ スクイブ カンパニー | タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元 |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| EP4317959A3 (en) * | 2018-03-19 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| JP2023509902A (ja) * | 2019-12-27 | 2023-03-10 | インターオリゴ・コーポレイション | 癌治療用免疫抗癌組成物 |
| US20240317873A1 (en) * | 2021-03-16 | 2024-09-26 | City Of Hope | Anti-hvem antibodies |
| CN114807038B (zh) * | 2022-02-11 | 2023-11-10 | 四川大学华西第二医院 | 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 |
| KR20250042144A (ko) * | 2022-06-27 | 2025-03-26 | 포어신 테크놀로지 (베이징) 컴퍼니., 리미티드. | Itga2를 표적으로 하는 항체 및 이를 포함하는 항체-약물 접합체(antibody targeting itga2 and antibody-drug conjugate comprising the same) |
| WO2024244006A1 (zh) * | 2023-06-02 | 2024-12-05 | 昱言科技(北京)有限公司 | 靶向itga2的抗体、其抗体药物缀合物以及用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5858709A (en) | 1996-10-15 | 1999-01-12 | Smithkline Beecham P.L.C. | Fibronectin binding protein B compounds |
| US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US20020160970A1 (en) | 1996-04-10 | 2002-10-31 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| HRP20150691T1 (hr) * | 2005-11-18 | 2015-11-06 | Glenmark Pharmaceuticals S.A. | Anti-alfa2 integrin protutijela i njihova uporaba |
| CN101378782A (zh) * | 2005-12-21 | 2009-03-04 | 惠氏公司 | 粘度降低的蛋白质制剂及其用途 |
| US20080267978A1 (en) * | 2006-08-28 | 2008-10-30 | Mary Zutter | Anti-angiogenic targets for cancer therapy |
| EA201190002A1 (ru) * | 2008-11-06 | 2012-04-30 | Гленмарк Фармасьютикалс С.А. | Лечение антителами к интегрину альфа-2 |
-
2009
- 2009-11-05 EA EA201190002A patent/EA201190002A1/ru unknown
- 2009-11-05 MX MX2011004696A patent/MX2011004696A/es active IP Right Grant
- 2009-11-05 JP JP2011533849A patent/JP5775458B2/ja not_active Expired - Fee Related
- 2009-11-05 EP EP09756355A patent/EP2346903A1/en not_active Withdrawn
- 2009-11-05 CA CA2742899A patent/CA2742899A1/en not_active Abandoned
- 2009-11-05 NZ NZ592436A patent/NZ592436A/xx not_active IP Right Cessation
- 2009-11-05 WO PCT/IB2009/007351 patent/WO2010052556A1/en not_active Ceased
- 2009-11-05 AU AU2009312532A patent/AU2009312532B2/en not_active Ceased
- 2009-11-06 US US12/614,178 patent/US8298531B2/en not_active Expired - Fee Related
-
2011
- 2011-04-26 CL CL2011000931A patent/CL2011000931A1/es unknown
- 2011-06-06 DK DKPA201170284A patent/DK201170284A/en not_active Application Discontinuation
-
2012
- 2012-08-23 US US13/593,285 patent/US20130084285A1/en not_active Abandoned
-
2015
- 2015-03-25 JP JP2015062978A patent/JP2015145397A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012507499A5 (OSRAM) | ||
| DK201170284A (en) | Treatment with anti-alpha2 integrin antibodies | |
| CN109153724B (zh) | 通过施用pd-1抑制剂治疗皮肤癌的方法 | |
| TWI417106B (zh) | 巨噬細胞-刺激蛋白質受體（ｒｏｎ）之抑制及其治療方法 | |
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| JP2019506403A5 (OSRAM) | ||
| JP2018536624A5 (OSRAM) | ||
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| JP2017186337A5 (OSRAM) | ||
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| JP2017510559A5 (OSRAM) | ||
| JP2012102109A5 (OSRAM) | ||
| JP2013510868A5 (OSRAM) | ||
| JP2010535713A5 (OSRAM) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| IL292758A (en) | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer | |
| CN115697419A (zh) | 多聚体抗dr5结合分子与癌症疗法组合治疗癌症的用途 | |
| JP2020511481A5 (OSRAM) | ||
| CN108350080A (zh) | 用于癌症的联合疗法 | |
| CN106068126A (zh) | 用于癌症的抗‑met联合抗‑vegfr2抗体的疗法 | |
| WO2021129616A1 (zh) | 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法 | |
| CA3201519A1 (en) | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer | |
| EP4408464A1 (en) | Methods of treating cancer and the pharmaceutical compositions thereof | |
| US20230248855A1 (en) | Her3 radioimmunotherapy for the treatment of solid cancers | |
| CN113365659B (zh) | 抗pd-l1抗体治疗头颈癌的用途 |